PBLA (Panbela Therapeutics) Scaled Net Operating Assets: -1.27 (As of Sep. 2024)


What is Panbela Therapeutics Scaled Net Operating Assets?

Panbela Therapeutics PBLA +2,400.00% Scaled Net Operating Assets is -1.27 as of Sep. 2024.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Panbela Therapeutics's operating assets for the quarter that ended in Sep. 2024 was $5.03 Mil. Panbela Therapeutics's operating liabilities for the quarter that ended in Sep. 2024 was $16.94 Mil. Panbela Therapeutics's Total Assets for the quarter that ended in Jun. 2024 was $9.41 Mil. Therefore, Panbela Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2024 was -1.27.

Panbela Therapeutics Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Panbela Therapeutics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Panbela Therapeutics Scaled Net Operating Assets Chart

Panbela Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.11 -0.18 -0.17 -0.19 -0.42

Panbela Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 -0.20 0.06 -0.61 -1.27

PBLA vs VINC, OMGAQ, ENDV: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Panbela Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Panbela Therapeutics Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Panbela Therapeutics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Panbela Therapeutics's Scaled Net Operating Assets falls into.


Panbela Therapeutics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Panbela Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(9.224-11.318)/4.978
=-0.42

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=11.802 - 2.578
=9.224

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=16.512 - 4.194 - 1
=11.318

Panbela Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Sep. 2024 )
=(Operating Assets (Q: Sep. 2024 )-Operating Liabilities (Q: Sep. 2024 ))/Total Assets (Q: Jun. 2024 )
=(5.026-16.942)/9.414
=-1.27

where

Operating Assets(Q: Sep. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=5.168 - 0.142
=5.026

Operating Liabilities(Q: Sep. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=23.336 - 3.194 - 3.2
=16.942

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of -1.27 mean?
Panbela Therapeutics (PBLA) has a Scaled Net Operating Assets of -1.27 as of Sep. 2024. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Panbela Therapeutics and its competitors.
Is Panbela Therapeutics' Scaled Net Operating Assets too high?
Panbela Therapeutics' current Scaled Net Operating Assets is -1.27.
How does Panbela Therapeutics' Scaled Net Operating Assets compare to VINC and OMGAQ?
Panbela Therapeutics' Scaled Net Operating Assets of -1.27 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Panbela Therapeutics and its competitors. Panbela Therapeutics's current Scaled Net Operating Assets is -1.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panbela Therapeutics stock overvalued right now?
Panbela Therapeutics (PBLA) has a current Scaled Net Operating Assets of -1.27. The current Scaled Net Operating Assets is -1.27. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Panbela Therapeutics (PBLA), the current Scaled Net Operating Assets is -1.27 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Panbela Therapeutics Business Description

Address 712 Vista Boulevard, Suite 305, Waconia, MN, USA, 55387
Panbela Therapeutics Inc is a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company's pipeline assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X), which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity.